犬类模型中自体组织疫苗癌症免疫疗法的安全性评估
Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model.
作者信息
Crossley Rachel A, Matz Alyssa, Dew Terry, Kalinauskas Ashley, Faucette Nicole, Poff Brad, Silbart Lawrence K, Suckow Mark A
机构信息
Department of Pathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, CT, U.S.A.
Department of Molecular and Cell Biology, College of Liberal Arts and Sciences, University of Connecticut, Storrs, CT, U.S.A.
出版信息
Anticancer Res. 2019 Apr;39(4):1699-1703. doi: 10.21873/anticanres.13275.
BACKGROUND/AIM: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model.
MATERIALS AND METHODS
An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis.
RESULTS
A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention.
CONCLUSION
Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.
背景/目的：先前在啮齿动物模型中的研究表明，自体组织疫苗是一种安全有效的癌症治疗方法；然而，作为向临床转化的一步，必须首先在更具临床相关性的模型中评估其安全性。
材料与方法
在一个具有临床相关性的犬类模型中评估了一种由切除肿瘤制备的自体免疫疗法的安全性。93只患有自发性肿瘤的犬接受了用灭活自体肿瘤组织与颗粒状猪小肠黏膜下层细胞外基质（SIS-ECM）佐剂联合的疫苗接种。对患者进行随访，以评估不良事件的发生情况、总生存期以及肿瘤复发和/或转移情况。
结果
少数（12%）患者出现了有限的、轻度发热、注射部位肿胀或嗜睡，所有这些症状均在未进行临床干预的情况下自行缓解。
结论
自体全细胞癌症免疫疗法可安全用于犬类癌症模型，是一种安全的癌症治疗方法。
Zotero 插件